For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $5.36 in the prior trading day, Abeona Therapeutics Inc (NASDAQ: ABEO) closed at $5.16, down -3.73%. In other words, the price has decreased by -$3.73 from its previous closing price. On the day, 1.4 million shares were traded. ABEO stock price reached its highest trading level at $5.37 during the session, while it also had its lowest trading level at $5.14.
Ratios:
Our goal is to gain a better understanding of ABEO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.74. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.09.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 22 ’26 when Vazzano Joseph Walter sold 18,666 shares for $5.33 per share. The transaction valued at 99,507 led to the insider holds 568,560 shares of the business.
Seshadri Vishwas sold 69,832 shares of ABEO for $372,267 on Jan 22 ’26. The Chief Executive Officer now owns 1,460,408 shares after completing the transaction at $5.33 per share. On Jan 22 ’26, another insider, O’Malley Brendan M., who serves as the SVP, Chief Legal Officer of the company, sold 13,578 shares for $5.33 each. As a result, the insider received 72,383 and left with 451,134 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 279627424 and an Enterprise Value of 96617424. As of this moment, Abeona’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.43. For the stock, the TTM Price-to-Sale (P/S) ratio is 699.07 while its Price-to-Book (P/B) ratio in mrq is 1.58. Its current Enterprise Value per Revenue stands at 241.544 whereas that against EBITDA is -1.193.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.17, which has changed by -0.02641511 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.54, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is 2.80%, while the 200-Day Moving Average is calculated to be -9.18%.
Shares Statistics:
The stock has traded on average 1.77M shares per day over the past 3-months and 1319100 shares per day over the last 10 days, according to various share statistics. A total of 52.40M shares are outstanding, with a floating share count of 48.99M. Insiders hold about 8.68% of the company’s shares, while institutions hold 63.55% stake in the company. Shares short for ABEO as of 1767139200 were 13246847 with a Short Ratio of 7.50, compared to 1764288000 on 13812286. Therefore, it implies a Short% of Shares Outstanding of 13246847 and a Short% of Float of 26.06.
Earnings Estimates
The dynamic stock of Abeona Therapeutics Inc (ABEO) is currently attracting attention from 3.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.05 and low estimates of -$0.15.
Analysts are recommending an EPS of between $1.33 and -$1.6 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.07, with 3.0 analysts recommending between $0.2 and -$0.36.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $18.67M. There is a high estimate of $24.9M for the next quarter, whereas the lowest estimate is $9.6M. Based on 7 analysts’ estimates, the company’s revenue will be $112.09M in the next fiscal year. The high estimate is $140.3M and the low estimate is $79.84M.
